Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Thermally induced gas flows in ratchet channels with diffuse and specular boundaries.

Shahabi V, Baier T, Roohi E, Hardt S.

Sci Rep. 2017 Jan 27;7:41412. doi: 10.1038/srep41412.

2.

Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy.

Shahabi V, Postow MA, Tuck D, Wolchok JD.

Am J Clin Oncol. 2015 Feb;38(1):90-7. doi: 10.1097/COC.0b013e3182868ec8. Review.

PMID:
25616204
3.

Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.

Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, Panting L, Jure-Kunkel M, Ji RR.

J Transl Med. 2013 Mar 22;11:75. doi: 10.1186/1479-5876-11-75.

4.

Listeria monocytogenes-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability.

Wallecha A, Wood L, Pan ZK, Maciag PC, Shahabi V, Paterson Y.

Clin Vaccine Immunol. 2013 Jan;20(1):77-84. doi: 10.1128/CVI.00488-12. Epub 2012 Nov 7.

5.

Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab.

Shahabi V, Whitney G, Hamid O, Schmidt H, Chasalow SD, Alaparthy S, Jackson JR.

Cancer Immunol Immunother. 2012 May;61(5):733-7. doi: 10.1007/s00262-012-1227-3. Epub 2012 Mar 1.

PMID:
22382362
6.

An immune-active tumor microenvironment favors clinical response to ipilimumab.

Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V.

Cancer Immunol Immunother. 2012 Jul;61(7):1019-31. doi: 10.1007/s00262-011-1172-6. Epub 2011 Dec 7.

PMID:
22146893
7.

Relationship between serum N-terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) level and the severity of coronary artery involvements.

Shahabi V, Moazenzadeh M, Azimzadeh BS, Nasri H, Afshar RM, Shahesmaili A, Rashidinejad H.

J Res Med Sci. 2011 Feb;16(2):143-8.

8.

Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment.

Shahabi V, Maciag PC, Rivera S, Wallecha A.

Bioeng Bugs. 2010 Jul-Aug;1(4):235-43. doi: 10.4161/bbug.1.4.11243. Epub 2010 Jan 4. Review.

9.

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.

Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R.

Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Review.

PMID:
21074069
10.

Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.

Shahabi V, Seavey MM, Maciag PC, Rivera S, Wallecha A.

Cancer Gene Ther. 2011 Jan;18(1):53-62. doi: 10.1038/cgt.2010.48. Epub 2010 Aug 20.

PMID:
20725099
11.

Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.

Ishizaki H, Song GY, Srivastava T, Carroll KD, Shahabi V, Manuel ER, Diamond DJ, Ellenhorn JD.

J Immunother. 2010 Jul-Aug;33(6):609-17. doi: 10.1097/CJI.0b013e3181e032c6.

12.

Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy.

Wood LM, Pan ZK, Shahabi V, Paterson Y.

Cancer Immunol Immunother. 2010 Jul;59(7):1049-1058. doi: 10.1007/s00262-010-0830-4. Epub 2010 Mar 6.

13.

Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.

Wallecha A, Carroll KD, Maciag PC, Rivera S, Shahabi V, Paterson Y.

Adv Appl Microbiol. 2009;66:1-27. doi: 10.1016/S0065-2164(08)00801-0. Review.

PMID:
19203646
14.

A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.

Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V.

Clin Cancer Res. 2009 Feb 1;15(3):924-32. doi: 10.1158/1078-0432.CCR-08-2283.

15.

Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.

Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V.

Clin Vaccine Immunol. 2009 Jan;16(1):96-103. doi: 10.1128/CVI.00274-08. Epub 2008 Nov 19.

16.

Development of a Listeria monocytogenes based vaccine against prostate cancer.

Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P.

Cancer Immunol Immunother. 2008 Sep;57(9):1301-13. doi: 10.1007/s00262-008-0463-z. Epub 2008 Feb 14.

PMID:
18273616
17.

Statistical evaluation for detection of peptide specific interferon-gamma secreting T-cells induced by HIV vaccine determined by ELISPOT assay.

Periwal SB, Spagna K, Shahabi V, Quiroz J, Shroff KE.

J Immunol Methods. 2005 Oct 30;305(2):128-34.

PMID:
16181634
18.

Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.

Sewell DA, Shahabi V, Gunn GR 3rd, Pan ZK, Dominiecki ME, Paterson Y.

Cancer Res. 2004 Dec 15;64(24):8821-5.

19.

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes.

Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR, Kast WM.

Vaccine. 2004 Jan 2;22(3-4):520-7.

PMID:
14670335
20.

Transport pathways for therapeutic concentrations of lithium in rat liver.

Shahabi V, van Rossum GD.

J Membr Biol. 1999 Nov 15;172(2):101-11.

PMID:
10556358
21.

Palmitoylation of the rat mu opioid receptor.

Chen C, Shahabi V, Xu W, Liu-Chen LY.

FEBS Lett. 1998 Dec 11;441(1):148-52.

22.

Structural basis for differential receptor binding of cholera and Escherichia coli heat-labile toxins: influence of heterologous amino acid substitutions in the cholera B-subunit.

Bäckström M, Shahabi V, Johansson S, Teneberg S, Kjellberg A, Miller-Podraza H, Holmgren J, Lebens M.

Mol Microbiol. 1997 May;24(3):489-97.

23.

Synthesis of hybrid molecules between heat-labile enterotoxin and cholera toxin B subunits: potential for use in a broad-spectrum vaccine.

Lebens M, Shahabi V, Bäckström M, Houze T, Lindblad N, Holmgren J.

Infect Immun. 1996 Jun;64(6):2144-50.

Supplemental Content

Loading ...
Support Center